Business Context and Reporting Period
OKYO Pharma Ltd, a foreign private issuer, filed this Form 6-K on March 12, 2026. The report details the partial exercise of an underwriter's option to purchase additional shares following a public offering that closed on February 17, 2026.
Key Financial Metrics
- Total Gross Proceeds: Approximately $22 million (before deducting underwriting discounts, commissions, and offering expenses).
- Shares Issued in Initial Offering: 10,815,000 ordinary shares at $1.85 per share.
- Shares Issued via Option Exercise: 1,109,060 ordinary shares at $1.85 per share.
- Total Shares Sold: 11,924,060 ordinary shares.
- Underwriter: Piper Sandler & Co. (Sole Manager).
Material Changes
The primary material change is the increase in capital raised through the partial exercise of the 30-day option granted to the underwriter. The underwriter purchased 1,109,060 of the 1,622,250 shares available under the option, increasing the total capital raised from the offering.
Outlook and Management Commentary
The filing confirms the transaction was conducted pursuant to an effective registration statement on Form F-3 (Registration No. 333-293145). The information is incorporated by reference into the registration statement. The filing does not provide specific forward-looking guidance, operational outlook, or management commentary beyond the transaction details.
Investor Verification Checklist
- Verify the exact net proceeds after deducting underwriting discounts and commissions.
- Confirm the intended use of the approximately $22 million in gross proceeds.
- Review the full prospectus supplement for details on the remaining unexercised option shares (513,190 shares).
- Check for any subsequent filings regarding the impact of this capital raise on the company's liquidity and operational runway.